














612Natural Killer Cell Killing of Acute Myelogenous
Leukemia and Acute Lymphoblastic Leukemia Blasts by
Killer Cell Immunoglobulin-Like Receptor–Negative
Natural Killer Cells after NKG2A and LIR-1 Blockade
Robert Godal,1 Veronika Bachanova,1 Michelle Gleason,1 Valarie McCullar,1 Gong H. Yun,1
Sarah Cooley,1 Michael R. Verneris,2 Philip B. McGlave,1 Jeffrey S. Miller1Although the study of natural killer (NK) cell alloreactivity has been dominated by studies of killer cell
immunoglobulin-like receptors (KIRs), we hypothesized that NKG2A and LIR-1, present on 53% 6 13% and
36% 6 18% of normal NK cells, respectively, play roles in the NK cell killing of primary leukemia targets.
KIR- cells, which composenearly half of the circulating NKcell population, exhibit tolerance toprimary leukemia
targets, suggesting signaling through other inhibitory receptors. Both acute myelogenous leukemia and acute
lymphoblastic leukemia targets were rendered susceptible to lysis by fresh resting KIR- NK cells when inhibitory
receptor–major histocompatibility class I interactions were blocked by pan-HLA antibodies, demonstrating that
these cells are functionally competent. Blockade of a single inhibitory receptor resulted in slightly increased kill-
ing, whereas combined LIR-1 and NKG2A blockade consistently resulted in increased NK cell cytotoxicity. Dual
blockade of NKG2A and LIR-1 led to significant killing of targets by resting KIR- NK cells, demonstrating that this
population is not hyporesponsive. Together these results suggest that alloreactivity of a significant fraction of
KIR- NK cells is mediated by NKG2A and LIR-1. Thus strategies to interrupt NKG2A and LIR-1 in combination
with anti-KIR blockade hold promise for exploiting NK cell therapy in acute leukemias.
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Human natural killer (NK) cells express several
families of inhibitory NK cell receptors that recognize
‘‘self’’ human leukocyte antigen (HLA) class I ligands.
These receptors act through several mechanisms to
determine whether or not a target will be susceptible to
NKcell–mediated lysis.Recognition of HLA class I by in-
hibitory receptors leads to self-tolerance by preventing
cytolysis of normal cells [1-4]. Although somewhat
paradoxical, the same self-receptors that lead to toleranceDivision of Adult Hematology, Oncology and Transplan-
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6/j.bbmt.2010.01.019also play a role in the acquisition of functional compe-
tence, a process termed NK cell education or licensing
[5-7]. Transient interruption of NK cell inhibitory
receptor signaling on educated NK cells may be
a therapeutic strategy for augmenting antitumor activity.
Three main inhibitory receptor families recognize
major histocompatibility class (MHC) class I molecules:
killer cell immunoglobulin-like receptors (KIRs),
CD94/NKG2A, and leukocyte immunoglobulin-like
receptor 1 (LIR-1). KIRs display specificity for
allele-specific variable regions of the alpha chain of
classical HLA class I (ie, HLA- A, -B, and -C). CD94/
NKG2A receptors recognize mainly nonclassical
HLA-E, whereas LIR-1 receptors recognize a broad
spectrum of classical HLA-A, -B, and -C and nonclassi-
cal HLA-E, -F, and -G by binding to conserved regions
of the alpha 3 domain [1,2,8-10]. Although 2 studies
investigating the inhibitory potential of LIR-1 on
primary peripheral blood (PB) NK cells found that
NK cell inhibition is largely attributed to HLA-G recog-
nition [11,12], the functional role of LIR-1 interactions
with primary leukemia cells remains poorly defined.
NK cells are the first immune cells to reconstitute
after hematopoietic cell transplantation (HCT),
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with the potential to control leukemia relapse in the
months preceding T cell reconstitution [13-15].
Although NK cell alloreactivity has been reported
for acute myelogenous leukemia (AML) and acute
lymphoblastic leukemia (ALL) after KIR ligand–
mismatched HCT [16-20], not all reports are in
agreement with this [21-24], and the mechanism of
apparent resistance in some studies is unclear. We
hypothesize that NK cell receptors other than KIRs
may explain these clinical results.MATERIALS AND METHODS
Cell Isolation and Cell Culture
All human samples were obtained after informed
consent was obtained following guidelines approved
by the University of Minnesota’s Committee on the
Use of Human Subjects in Research and in accordance
with the Declaration of Helsinki. Primary cells from
18 patients were collected by leukapheresis (AML,
n5 5; pre–B-ALL, n5 3; T-ALL, n5 1) and bone
marrow aspiration (AML, n5 5; pre–B-ALL, n5 4).
Blasts composed.80% of each sample. After thawing,
necrotic blasts were removed by density-gradient
centrifugation using Ficoll-Histopaque (Sigma-
Aldrich, St Louis, MO) and kept in Ham/F12 (Cellgro,
Manassas, VA), basal medium supplemented with
20% human AB serum (Valley Biomedical, Winches-
ter, VA) for 12 hours. NK cells were isolated from
PB mononuclear cells (PBMCs) obtained from 42
healthy donors through depletion of other cells by im-
munomagnetic beads (NK Cell Isolation Kit; Miltenyi
Biotech, Auburn, CA). KIR1 NK cells were positively
separated by staining with phycoerythrin (PE)-conju-
gated antibodies against CD158a (HP-3E4),
CD158b (CH-L), CD158e (DX9) (all from BD Biosci-
ences, San Jose, CA), and CD158i (FES172; Beckman
Coulter, Fullerton, CA), and subsequent selection us-
ing anti-PE beads (Miltenyi Biotech). KIR- NK cells
were isolated by positive depletion of KIR1 NK cells.
In addition, NK cells from unseparated blood mono-
nuclear cells 100 days after transplantation (autolo-
gous, n5 1; umbilical cord blood, n5 2; unrelated
adult donor, n5 2) were tested.KIR Ligand Typing, Reverse-Transcriptase
Polymerase Chain Reaction for HLA-G, and
Western Blot Analysis
KIR ligand typing was performed by pyrosequencing
as described by Yun et al. [25]. HLA-G transcripts were
amplified over 35 cycles of reverse-transcriptase
polymerase chain reaction (RT-PCR) using Platinum
Taq DNA polymerase (Invitrogen, Carlsbad, CA) with
published pan–HLA-G primer sets G.257F andG.1004R, as described previously [26]. As an internal
control, b-actin gene amplification was carried out for
each sample. HLA-E and HLA-G expression of primary
targets was determined by Western blotting with the
anti–HLA-E clone MEM–E/02 and anti–HLA-G clone
MEM–G/01 (Abcam, Cambridge, MA), as described
previously [27]. The choriocarcinoma cell line JEG-3
was used as a positive control, and the mouse cell line
EL08-1D2 was used as a negative control [28].
Flow Cytometry
Immunophenotypic analysis of cells was performed
using 4-color analysis on a FACSCalibur analyzer
with CELLQuest Pro software (BD Biosciences).
Cells were stained with the following monoclonal anti-
bodies (mAbs), as indicated: fluorescein isothiocyanate
(FITC)- or PE-conjugated DX9 (anti-CD158e),
HP-3E4 (anti-CD158a/h), and CH-L (158b); peridinin
chlorophyll A protein (PerCP)-conjugated SK7 (anti-
CD3); allophycocyanin (APC)-conjugated NCAM16.2
(anti-CD56) (BD Biosciences); and PE-conjugated
Z199 (anti-NKG2A) and HP-F1 (anti–LIR-1) (Beck-
man Coulter). HLA expression was analyzed by flow
cytometry using PE-conjugated pan–anti-HLA class
1 mAbs W6/32 (Abcam, Cambridge, MA) and
HP-1F7 (kindly provided by M. Lopez-Botet, Universi-
tat Pompeu Fabra, Barcelona, Spain).
Determination of NK Cell–Mediated
Cytotoxicity
Flow cytometric detection of NK cell–mediated
cytotoxicity was performed as described previously
[29-31]. In brief, tumor target cells were labeled with
3 mMol (dissolved in DMSO) green lipophylic
fluorescent dye DIOC18 (3,3’-dioctadecylox-acarbo
cyanine perchlorate; Sigma-Aldrich, St Louis, MO).
Effector cells and target cells were coincubated at var-
ious ratios for 4 hours, after which propidium iodide
was added at a final concentration of 5 mg/mL for
5 minutes to determine the proportion of dead cells.
The proportion of propidium iodide–positive cells
was determined by flow cytometry in the FL3 channel.
The HLA class I–deficient cell line K562 was used as
a positive control. Primary targets that exhibited
.10% specific cytolysis were considered sensitive to
killing.
Degranulation Assays
Degranulation was determined as described by Betts
et al. [32] and Rubio et al. [33]. Compared with cytotox-
icity assays, degranulation assays have the advantage of
being applicable to batch analysis of frozen samples
and provide additional data on the killing potential of
NK cell subsets. In brief, isolated resting or interleukin
(IL)-2–activated CD561/CD3- cells were coincubated
with target cells at an effector:target (E:T) ratio of 1:2
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Anti–CD107a-PE or anti-CD107a,b FITC antibody
clone H4A3 and clone H4B4 (BD Biosciences) were
added during the entire incubation period. After
1 hour of incubation, monensin (Sigma-Aldrich) was
added to a final concentration of 10 ug/mL. After an
additional 5 hours, cells were washed and stained with
anti-CD56 mAb. CD107 expression on NK cells was
analyzed by flow cytometry.
Antibody-Blocking Experiments
KIR blocking was performed with mAb IgG4
clone 1-7F9 (blocking KIR2DL1/2DL2/2DL3), and
NKG2A blocking was performed with mAb clone
Z270 (both from Novo Nordisk, Copenhagen,
Denmark). LIR-1 blocking was performed with mouse
mAb IgG2b clone 292319 (R&D Systems). Blocking
experiments were performed in medium supplemented
with 20% human AB serum. Mouse mAb IgG1 clone
HP-1F7 (kindly provided by M. Lopez Botet) was
used as a positive control for pan-HLA blocking.
The mAb clone HP-1F7 effectively binds to the alpha
chain of HLA-A, -B, -C, -E, and -G, and blocks all
NK cell inhibitory receptor engagement [10,34,35].
NK cells were preincubated for 30 minutes with NK
receptor–blocking antibodies to a final concentration
of 20 mg/mL, and target cells were preincubated for
30 minutes with anti-HLA mAb to a final concentra-
tion of 20 mg/mL, which was at least 10-fold higher
than the maximal saturating concentration. Mouse
anti-hNCAM/CD56 IgG2b clone 301040 and IgG2b
clone 20116.11 (R&D Systems) were used as isotype
controls.
Statistical Analysis
The Student t test was applied for statistical
evaluation of differences between groups.RESULTS
A High Frequency of KIR- Blood NK Cells
Express NKG2A and LIR-1
NK cells receptors from 3 families—KIR, NKG2A,
and LIR-1—recognize MHC class I molecules. The
surface expression of these receptors on KIR+ and
KIR- peripheral blood NK cells from 42 healthy donors
was measured by flow cytometry. Almost half of the NK
cells (45% 6 11%) lacked KIR expression, although
there was variability among donors (range, 28%-
79%). NKG2A and LIR-1 were expressed on 53% 6
13% (range, 20%-81%) and 36% 6 18% (range 5%-
80%) of all NK cells, respectively. The likelihood of
NKG2A and LIR-1 coexpression varied among the
KIR subsets (Table 1). NKG2A was more commonly
expressed on KIR- cells (KIR1/NKG2A1:KIR-/NKG2A1 ratio of 1:2.1; P \.0001), whereas LIR-1
was more likely coexpressed on KIR1 NK cells
(KIR1/LIR-11:KIR-/LIR-11 ratio of 2.3:1; P
\.0001). Some individuals displayed an inhibitory re-
ceptor pattern comprising predominantly KIR, whereas
others expressed a decreased percentage of KIR1 cells
and an NKG2A-dominant pattern (Figure 1A).
Primary Acute Leukemia Blasts Express
NKG2A and LIR-1 Ligands
The cognate ligands for NKG2A and LIR-1 were
measured on primary AML (n5 5) and primary ALL
blasts (n5 4). All targets expressed HLA class I mole-
cules on the surface, as detected by a pan-HLA antibody
recognizing HLA-A, -B, -C, -E, and -G. Class I expres-
sion was consistently higher on ALL blasts compared
with AML blasts (mean fluorescence intensity,
2446 52 [n5 4] vs 706 30 [n5 5]; P5 .0004), sug-
gesting that more inhibition by HLA class I molecules
may explain the relative resistance of ALL to NK cell–
mediated killing [36]. All leukemia blasts also expressed
HLA-E, the ligand for NKG2A, as measured by West-
ern blot analysis [21] (data not shown). LIR-1 ligands
are less definitively characterized but are thought to
include HLA-G and other classical MHC ligands.
Although the MHC is variably expressed by leukemia,
the expression of HLA-G on primary leukemia remains
unclear [37,38]. Western blot analysis detected no
HLA-G protein in any of the primary leukemia samples
used in this study. Because the sensitivity of the anti–
HLA-G antibody is not well documented and the spec-
ificity of anti–HLA-G antibodies is uncertain [39], we
also used RT-PCR to measure HLA-G transcripts in
the samples. No HLA-G transcripts were found in
5 of 9 samples tested, supporting the conclusion that
they were truly HLA-G negative (Figure 1C). The
low levels of HLA-G1 (770 bp) and HLA-G2/-G4
(490 bp) transcripts detected in 4 of 9 leukemia samples
did not result in expression of detectable HLA-G pro-
tein and likely represent low-level HLA-G transcripts
that have been found in normal PB [40].
KIR, NKG2A, and LIR-1 Contribute to
Alloreactivity against Primary AML and ALL
Blasts
To characterize the contributions of KIR,
NKG2A, and LIR-1 blockade to NK cell–mediated
alloreactivity against leukemia, we tested the ability of
polyclonal allogeneic NK cells to kill primary AML
and ALL blasts in the presence and absence of blocking
mAbs. Cytotoxicity and degranulation were tested
using fresh resting NK cells without confounding
effects of exogenous cytokines. For pan-HLA block-
ade, we selected the antibody clone HP-1F7 because
it binds to the alpha chain of HLA-A, -B, -C, -E, and
-G to functionally block multiple HLA interactions
Table 1. Inhibitory NK Receptor Expression on KIR+ and KIR- NK Cells
Receptor KIR+ Population KIR- Population n P Value
NKG2A+* 35% ± 13% 75% ± 12% 42 <.0001
LIR-1+* 44% ± 20% 27% ± 14% 42 <.0001
NKG2A+LIR-I+* 11.2% ± 7.4% 7.6% ± 6.1% 7 NS
NKG2A+LIR-I-* 16.9% ± 9.4% 44% ± 15% 7 <.0001
NKG2A-LIR-I+* 30% ± 19% 13% ± 12% 7 .01
NKG2A-LIR-I-* 41% ± 18% 35% ± 7.2% 7 NS
KIR+† 87% ± 7.6% 7.8% ± 5.3% 15 <.0001
KIR-NKG2A-LIR-I- 16% ± 2.7% of total NK cells (n5 7)
NS indicates not significant.
*Mean percentage (6 SD) of each receptor expressed on gated KIR+ and KIR- NK cells determined by flow cytometry before bead separation.
†Percentage of each receptor on KIR+ and KIR- NK cells after bead separation.
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can block all KIR, and so we focused on an antibody
currently in clinical deevelopment (anti-2DL1/
2DL2/2DL3), which interacts with all HLA-C1 and
HLA-C2 ligands. Other blocking antibodies were
used individually or in combinations as indicated.
Fresh polyclonal NK cells potently lysed HLA
class I–negative K562 cell targets used as a control
for their broad cytotoxicity. Lysis of primary leukemia
targets was always significantly less. Pan-HLA block-
ade resulted in increased target lysis by resting
NK cells for both AML targets (3-fold; n5 2;Figure 1. NK cells express KIR, NKG2A, and LIR-1, and leukemia targets mi
cytometry for the expression of class I–recognizing inhibitory receptors (n5 4
pression of NKG2A and LIR-1 on KIR-expressing cells (using a cocktail recogn
tative examples from a donor with a KIR-dominant phenotype and an NKG2A-d
populations and KIR- population using anti-PE–conjugated immunomagnetic be
KIR+ and KIR- populations are shown. KIR- NK cells coexpress a high proportio
used to test for alternatively spliced HLA-G on 9 leukemia samples, the erythr
cinoma cell line (JEG-3) as a positive control. b-actin was used as an internal cP\.0005) and ALL targets (6-fold; n5 2; P\.0005)
compared with no blockade (Figure 2A and
Supplemental Figure 1A). Clinically achievable KIR
blockade using an anti-KIR reagent increased the level
of cytotoxicity against AML and ALL blasts slightly,
but not to the level of pan-HLA blockade, suggesting
that other class I–recognizing receptors were function-
ally operant. AML blasts (AML3) lacking 2 KIR li-
gands (HLA-C2 and HLA-Bw4) were slightly more
sensitive to killing without blockade by allogeneic
NK cell donors mismatched in both ligands (n5 3)
compared with completely matched donors (n5 3)nimally express HLA-G transcripts. (A) NK cells were evaluated by flow
2). Each CD561/CD3- NK cell population was gated to evaluate the ex-
izing KIR2DL1/S1, KIR2DL2/L3/S2, and KIR3DL1). Shown are represen-
ominant phenotype. (B) NK cells were then enriched into KIR+ and KIR-
ads recognizing a cocktail of anti-KIR mAbs. Representative examples of
n of NKG2A and less LIR-1. (C) RT-PCR and Southern blot analysis were
oleukemia cell line K562, 2 normal PBMC populations, and a choriocar-
ontrol.
Figure 2. KIR, NKG2A, and LIR-1 blockade all contribute to cytotoxicity against primary AML. (A) Primary AML blasts from 2 patients, AML4 (i, ii)
(tested with 5 allogeneic NK cell donors) and AML3 (iii, iv) (tested with 6 allogeneic donors), were investigated for their susceptibility to cytolysis me-
diated by resting NK cells (i, iii) at an E:T ratio of 5:1. (B) Degranulation of resting NK cells (ii, iv) was determined by CD107a expression following
coincubation with AML4 blasts (ii) (3 NK cell donors) and AML3 blasts (iv) (6 NK cell donors). Mean 6 standard error of the mean from different
NK cell donors are shown. Pan-HLA blockade was compared with blockade of KIR, NKG2A, and LIR-1 individually and in combinations. Statistically
significant differences between groups are noted (*P\.05; **P\.001; ***P\.005; ****P\.0005). HLA-B and -C ligand status of leukemia blasts is shown.
There was KIR ligand match in 3 donors and mismatch in 2 KIR ligands in 3 donors used for AML3.
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of NKG2A blockade was similar to that of KIR block-
ade. The combination of LIR-1 blockade with either
KIR or NKG2A blockade resulted in strongly in-
creased killing of both AML and ALL targets. These
results indicate that all 3 receptors have the potential
to inhibit NK cell cytotoxicity.
In samples negative for HLA-G transcripts and
protein, indicating a lack of HLA-G expression,
LIR-1 blockade enhanced killing of blasts from these
patients. This suggests that the engagement of classical
and/or nonclassical HLA class I molecules other than
HLA-G on primary blasts can inhibit NK cell killing
through LIR-1. Measurement of the degranulation re-
sponse by CD107a yielded similar results (Figure 2B
and Supplemental Figure 1B). Dual blockade of KIR
and LIR-1 or of NKG2A and LIR-1 resulted in an
increased proportion of degranulating NK cells,
comparable to that achieved with pan-HLA blockade.KIR- NK Cells Exhibit Significant Cytotoxicity
against Primary Leukemia Blasts
To further study the differential function of
non-KIR receptors against primary leukemia targets,
KIR1 and KIR- NK cells were separated from 15
healthy donors using a cocktail of anti-KIR mAbs
(Figure 1B and Table 1). Both populations lysed class
I–negative K562 targets; however KIR- NK cells
exhibited less killing than KIR1 cells (56% 6 8%
[n5 5] vs 39% 6 16% [n5 11] at an E:T ratio of
5:1; P5 .02). Cytotoxicity assays were then performed
against primary AML and ALL blasts (Figures 3A and
4A). Pan-HLA blockade of both AML and ALL blasts
resulted in potent cytotoxicity by resting KIR1 and
KIR- NK cells against both targets. Similar to the
results obtained using unsorted NK cells, blockade
of both NKG2A and LIR-1 in the KIR- NK cell pop-
ulation resulted in a 3.1-fold (P \.01) and 2.3-fold
(P\.01) increase in cytotoxicity, respectively, against
Figure 3. KIR- NK cells exhibit significant alloreactivity against primary AML blasts. Primary AML blasts (AML3) were investigated for their susceptibility
to KIR-enriched (KIR1) and KIR--resting (4 NK cell donors) NK cells in cytotoxicity (A) and degranulation (B) assays. Lysis or degranulation are shown
with NK cells alone against leukemia targets (control) and the presence of the indicated blocking antibodies, or against K562 targets. Statistically significant
differences between groups are marked (*p\0.05; **p\0.01; ***p\0.005).
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ade. Similar results were obtained using CD107a
degranulation (Figures 3B and 4B).
Maximal Killing of Primary AML and ALL Blasts
Requires NKG2A and LIR-1 Blockade along with
KIR Blockade
The aforementioned studies demonstrated that
KIR- NK cells are not hyporesponsive and are capable
of lysing targets. To better characterize the contribution
of antileukemic killing by the 3 families of inhibitory
receptors, we measured the sensitivity of additional pri-
mary AML and ALL blasts to killing by polyclonal rest-
ing NK cells (Supplemental Figure 2). One of 9 AML
samples and 1 of 7 ALL samples were completely resis-
tant to NK cell–mediated lysis. Consistent with the cy-
totoxicity findings, neither resistant sample induced
degranulation of NK cells (data not shown). We then
characterized the sensitivity to alloreactive NK cell–
mediated killing by setting a threshold of at leasta 10% increment in specific lysis with pan-HLA block-
ade. Based on this definition, 2 AML samples that were
killed by resting NK cells at baseline were not sensitive
to NK alloreactivity after pan-HLA blockade or com-
bined blockade of inhibitory receptors. Six of 9 AML
samples and 6 of 7 ALL samples (including 1 T-ALL
sample) demonstrated sensitivity to alloreactive NK
cells, with pan-HLA blockade resulting in increased
killing. Individual blockade of KIR, NKG2A, or LIR-
1 resulted in modest increases in leukemia lysis, but
the effects were significantly less that those seen with
pan-HLA blockade in AML (23.9% 6 3.7% vs 7.8%
6 2.3%; n 5 6; P\.005) and in ALL (24.7% 6 3.9%
vs 8.21% 6 2.3%; n5 6; P\.005). Blockade of 2 or
more receptors resulted in increased leukemia killing.
Furthermore, blockade of KIR, NKG2A, and LIR-1
achieved the same level of killing obtained with the
pan-HLA antibody, suggesting that the 3 receptor fam-
ilies account for most of the MHC class I interactions
between bulk NK cells and leukemia blasts.
Figure 4. KIR- NK cells exhibit significant alloreactivity against primary ALL blasts. Primary ALL blasts (ALL9) were investigated for their susceptibility
to KIR-enriched (KIR1) and KIR--resting (4 NK cell donors) NK cells in cytotoxicity (A) and degranulation (B) assays.
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Posttransplantation NK Cells with Inhibitory
Receptor Blockade
We have previously shown that despite a 4-fold
increase in the percentage of NK cells reconstituting
in the PB 100 days after transplantation, the NK cell
receptor repertoire in recipients of T cell–replete trans-
plants is perturbed. KIRs are diminished, and NKG2A
is the dominant inhibitory receptor (expressed on
. 80% NK cells) [15]. We found that LIR-1 expression
was diminished, occurring on only20% of NK cells at
this time point posttransplantation (data not shown).
These results suggest that NKG2A and LIR-1 might
be ideal for inducing posttransplantation NK cell reac-
tivity. Five patients were studied at 100 days post-
transplantation to explore whether NK cells are
functional and to determine their tolerance mechanism
against primary allogeneic leukemia blasts. AML or
ALL targets known to be sensitive to enhanced killing
after interruption of HLA class I interactions between
normal donor NK cells and targets were used. Giventhe unscheduled nature of receipt of patient samples,
PBMCs were incubated in 5 U/mL of IL-2 for 48 hours
before testing, to allow thawing and preparation of tar-
gets. This concentration and duration of IL-2 exposure
did not alter the expression of KIR, NKG2A, or LIR-1
(n5 5; data not shown). In this setting, KIR blockade
had no effect on killing compared with control condi-
tions; however, the addition of NKG2A, LIR-1, or
a combination of all 3 blocking antibodies significantly
increased killing, demonstrating that NK cells are func-
tional in a setting in which non-KIR class I recognizing
receptors dominate (Figure 5).DISCUSSION
Tolerance to allogeneic NK cell killing is gener-
ally attributed to the inhibitory effects of KIRs. Our
findings suggest that simply overcoming KIR inhibi-
tion may be insufficient to maximize killing of pri-
mary leukemia targets. In fact, in some settings in
which KIR expression is low, this tolerance
Figure 5. Enhanced killing by NK cells 100 days after allogeneic HCT by NKG2A and LIR-1 blockade. PBMCs from patients 100 days posttransplanta-
tion were tested against NK cell–susceptible AML (n5 3) and ALL (n5 2) primary blasts alone or with anti-KIR, LIR-1, or NKG2A blockade or a com-
bination (combo). Representative (A) and aggregate (B) data are shown. *P\.05.
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anti-KIR reagent (binding to KIR2DL1, L2, and
L3) was recently reported to effectively enhance kill-
ing of leukemia targets, it does not block all inhibi-
tory KIRs, because KIR3DL1 is not bound [41].
But, nearly half of our AML targets were Bw4-
negative, supporting the notion that KIR3DL1 inter-
actions cannot explain the lack of response to KIR
blockade seen in that study. This finding prompted
us to assess the importance of other inhibitory NK
cell receptors in the recognition and killing of acute
leukemia cells. In the present study, we have demon-
strated that 2 other families of inhibitory receptors—
NKG2A and LIR-1—are present on both KIR1 and
KIR- NK cells and are implicated in NK cell toler-
ance of primary AML and ALL blasts.
Our findings indicate that LIR-1 interactions can
occur in the absence of HLA-G (a high-affinity ligand),
supporting the observation that LIR-1 recognizes
other HLA class I molecules [9,10,35,42]. This is in
contrast to findings reported by Riteau and
coworkers [11,12] that a ‘‘dim’’ level of LIR-1 expres-
sion on primary PB NK cells is incapable of mediating
significant inhibitory signals by HLA class I molecules.
The KIR-/NKG2A1 NK cell population is dominant
in NK cells residing in lymphoid tissue, in the PB of
some healthy individuals, and in most patients post-
transplantation [15,43,44]. All AML and ALL
samples that we tested expressed the NKG2A ligand
HLA-E. Our findings demonstrate that resting poly-
clonal KIR-/NKG2A1 NK cell populations from do-
nors exhibit potent cytotoxicity against primary
blasts, in agreement with the findings of an NK cell
clone study by Yawata et al. [45] using HLA class I–de-
ficient targets. Our KIR- NK cell results may be partic-
ularly important in patients reconstituting early after T
cell–replete transplantation, where KIR- NK cells pre-
dominate. The results may be different in a T cell–depleted setting. Yu et al. [46] recently reported that
tolerance to self may be broken early after transplanta-
tion, but reestablished later. Although further kinetic
studies with various graft sources (eg, adult donor, um-
bilical cord blood) are needed to fully explore NK cell
function in vivo, our data nonetheless support the no-
tion that NKG2A and LIR-1 blockade may be more
important posttransplantation given the perturbed
KIR repertoire in that setting.
Our results demonstrate that primary AML and
ALL blasts effectively protect themselves against
cytolysis from KIR- NK cells through MHC interac-
tions with NKG2A and LIR-1. This resistance can
be diminished by combined blockade of these inhibi-
tory receptors. The tight correlation between cytotox-
icity and degranulation will allow us to measure NK
cell subsets responsible for this activity to better un-
derstand this process. We acknowledge that other fac-
tors also are important in determining tumor kill. NK
cell function is determined by the net sum of inhibi-
tory signals, but activating receptor signals are also re-
quired for NK cell killing. Studies of activating
receptors and how they reconstitute after HCT are
needed to fully elucidate the role of NK cells in
a graft-versus-leukemia effect. Although the func-
tional competence of KIR-/NKG2A1 NK cell recon-
stitution after HCT could possibly be adversely
affected by posttransplantation immunosuppression,
our data support the concept that inhibitory receptor
blockade enhances leukemia killing. A comprehensive
analysis of NK cell function after transplantation has
been initiated to explore whether combining inhibitory
receptor blockade with other strategies, such as IL-2 or
IL-15 administration, might improve transplantation
outcomes, and whether in vitro function correlates
with clinical efficacy.
Our work also provides insight into ALL resistance
to NK alloreactivity. ALL blasts exhibit substantially
620 Biol Blood Marrow Transplant 16:612-621, 2010R. Godal et al.higher HLA class I expression compared with myelog-
enous blasts, as shown here. Importantly, the resis-
tance of ALL blasts to NK cell–mediated killing can
be overcome by pan-HLA blockade. The blockade of
multiple MHC class I–recognizing receptors can me-
diate robust NK cytotoxicity against ALL blasts, sim-
ilar to that achieved in AML, supporting the
therapeutic potential of inhibitory NK cell receptor
blockade in patients with ALL.
In summary, our results show that inhibitory
receptors other than KIR endow polyclonal bulk NK
cells with self-tolerance mechanisms through NKG2A
and LIR-1. The patterns of KIR, NKG2A, and LIR-1
expression on NK cells and the expressions of their
cognate ligands on leukemia blasts determine the
magnitude of potential inhibition by self MHC class I.
Screening of donor NK cells against patients’ leukemia
blasts may be used to exclude patients who exhibit a pri-
mary NK cell resistance pattern from adoptive NK cell
therapy trials.’’ Simultaneous blockade of more than
one inhibitory receptor family significantly increases
the frequency of alloreactive NK cells. Our findings
warrant clinical testing of KIR, NKG2A, and LIR-1
blockade (alone and in combination) to increase the ef-
ficacy of NK cell–based therapies in the treatment of
leukemia and other class I–expressing malignancies, es-
pecially in patients undergoing HCT, in which non-
KIR mechanisms may dominate.ACKNOWLEDGMENTS
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